{
 "cells": [
  {
   "cell_type": "code",
   "execution_count": 1,
   "metadata": {},
   "outputs": [],
   "source": [
    "import pdfminer\n",
    "from PyPDF2 import PdfFileReader\n",
    "import nltk\n",
    "import numpy as np\n",
    "import re\n",
    "import sys\n",
    "reload(sys)\n",
    "sys.setdefaultencoding('utf8')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "metadata": {},
   "outputs": [],
   "source": [
    "from pdfminer.pdfinterp import PDFResourceManager, PDFPageInterpreter#process_pdf\n",
    "from pdfminer.pdfpage import PDFPage\n",
    "from pdfminer.converter import TextConverter\n",
    "from pdfminer.layout import LAParams\n",
    "\n",
    "from cStringIO import StringIO\n",
    "\n",
    "def pdf_to_text(pdfname):\n",
    "\n",
    "    # PDFMiner boilerplate\n",
    "    rsrcmgr = PDFResourceManager()\n",
    "    sio = StringIO()\n",
    "    codec = 'utf-8'\n",
    "    laparams = LAParams()\n",
    "    device = TextConverter(rsrcmgr, sio, codec=codec, laparams=laparams)\n",
    "    interpreter = PDFPageInterpreter(rsrcmgr, device)\n",
    "\n",
    "    # Extract text\n",
    "    fp = file(pdfname, 'rb')\n",
    "    for page in PDFPage.get_pages(fp):\n",
    "        interpreter.process_page(page)\n",
    "    fp.close()\n",
    "\n",
    "    # Get text from StringIO\n",
    "    text = sio.getvalue()\n",
    "\n",
    "    # Cleanup\n",
    "    device.close()\n",
    "    sio.close()\n",
    "\n",
    "    return text"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "metadata": {},
   "outputs": [],
   "source": [
    "text = pdf_to_text(\"/Users/itziar/Downloads/DS_NLP_Assignment_final/WC500057122.pdf\")\n",
    "lines = list(filter(bool,text.split('\\n')))\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 4,
   "metadata": {},
   "outputs": [],
   "source": [
    "def get_specific_section(section_name):\n",
    "    end_section = ''\n",
    "    for i in range(len(lines)):\n",
    "        start_section = '[0-9]+.[0-9]+  '+  section_name\n",
    "        if re.match(start_section, lines[i]):\n",
    "            start_section_number = lines[i].split()[0]\n",
    "            start_section_head = ''.join(re.findall('[0-9]+.', start_section_number))\n",
    "            start_section_name = lines[i]\n",
    "\n",
    "            end_section_number = start_section_head + str(int(start_section_number[-1]) + 1)\n",
    "            end = end_section_number + '  [A-Za-z]*'\n",
    "    end_section += end\n",
    "    \n",
    "    for i in range(len(lines)):\n",
    "        if re.match(end_section, lines[i]):\n",
    "            end_section_name = lines[i]\n",
    "    str1 = text[text.find(start_section_name)+len(start_section_name):text.rfind(end_section_name)]\n",
    "    return str1"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "metadata": {},
   "outputs": [],
   "source": [
    "str1 = get_specific_section('Quality aspects')"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "metadata": {},
   "outputs": [],
   "source": [
    "str1 = str1.replace(\"\\n\",\"\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 7,
   "metadata": {},
   "outputs": [],
   "source": [
    "CLUSTER_THRESHOLD = 5\n",
    "TOP_SENTENCES = 100"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 8,
   "metadata": {},
   "outputs": [],
   "source": [
    "def _score_sentences(sentences, important_words):\n",
    "    scores = []\n",
    "    sentence_idx = -1\n",
    "    \n",
    "    for s in [nltk.tokenize.word_tokenize(s) for s in sentences]:\n",
    "        sentence_idx += 1\n",
    "        word_idx = []\n",
    "        \n",
    "        #For each word in the word list...\n",
    "        for w in important_words:\n",
    "            try:\n",
    "                #Compute an index for where any important word occurs in the sentence.\n",
    "                word_idx.append(s.index(w))\n",
    "            except ValueError as e: # w not in this particular sentence\n",
    "                pass\n",
    "            \n",
    "        word_idx.sort()\n",
    "        \n",
    "        #It is possible that some sentences may not contain any important words at all.\n",
    "        if len(word_idx) == 0: continue\n",
    "            \n",
    "        #Using the word index, compute clusters by using a max distance threshold for any two consecutive words\n",
    "        \n",
    "        clusters = []\n",
    "        cluster = [word_idx[0]]\n",
    "        i = 1\n",
    "        while i < len(word_idx):\n",
    "            if word_idx[i] - word_idx[i-1] < CLUSTER_THRESHOLD:\n",
    "                cluster.append(word_idx[i])\n",
    "            else:\n",
    "                clusters.append(cluster[:])\n",
    "                cluster = [word_idx[i]]\n",
    "            i += 1\n",
    "        clusters.append(cluster)\n",
    "        \n",
    "        #Scores for each cluster. The max score for any given cluster is the score for the sentence.\n",
    "        \n",
    "        max_cluster_score = 0\n",
    "        for c in clusters:\n",
    "            significant_words_in_cluster = len(c)\n",
    "            total_words_in_cluster = c[-1] - c[0] + 1\n",
    "            score = 1.0 * significant_words_in_cluster \\\n",
    "                    * significant_words_in_cluster / total_words_in_cluster\n",
    "            \n",
    "            if score > max_cluster_score:\n",
    "                max_cluster_score = score\n",
    "                \n",
    "        scores.append((sentence_idx, score))\n",
    "    return scores"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 9,
   "metadata": {},
   "outputs": [],
   "source": [
    "def summarize(txt):\n",
    "    sentences = [s for s in nltk.tokenize.sent_tokenize(str1)]\n",
    "    normalized_sentences = [s.lower() for s in sentences]\n",
    "    words = [w.lower() for sentence in normalized_sentences for w in nltk.tokenize.word_tokenize(sentence)]\n",
    "    fdist = nltk.FreqDist(words)\n",
    "    top_n_words = [w[0] for w in fdist.items()\n",
    "                  if w[0] not in nltk.corpus.stopwords.words('english')][:]\n",
    "    scored_sentences = _score_sentences(normalized_sentences, top_n_words)\n",
    "\n",
    "    #Summarization Approach 1:\n",
    "    #Filter out nonsignificant sentences by using the average scores plus a fraction of the std dev as a filter\n",
    "\n",
    "    avg = np.mean([s[1] for s in scored_sentences])\n",
    "    std = np.std([s[1] for s in scored_sentences])\n",
    "    mean_scored = [(sent_idx, score) for (sent_idx, score) in scored_sentences \n",
    "                   if score > avg + 0.5 * std]\n",
    "\n",
    "    #Summarization Approach 2:\n",
    "    #Another approach would be to return only the top N ranked sentences\n",
    "\n",
    "    top_n_scored = sorted(scored_sentences, key=lambda s: s[1])[-TOP_SENTENCES:]\n",
    "    top_n_scored = sorted(top_n_scored, key=lambda s:s[0])\n",
    "    \n",
    "    return dict(top_n_summary = [sentences[idx] for (idx, score) in top_n_scored], \n",
    "               mean_scored_summary = [sentences[idx] for (idx, score) in mean_scored])\n",
    "\n",
    "\n"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 10,
   "metadata": {},
   "outputs": [],
   "source": [
    "ll = summarize(str1)"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 13,
   "metadata": {},
   "outputs": [
    {
     "data": {
      "text/plain": [
       "{'mean_scored_summary': ['Other ingredients in the core tablet include cellulose microcrystalline, croscarmellose sodium, hypromellose  5  cp,  lactose  monohydrate,  magnesium  stearate  and  sodium  laurilsulfate.',\n",
       "  'The  film coating contains ferric oxide red, hypromellose 15 cp, macrogol 3350 and titanium dioxide  The  tablets  are  packaged  in  thermoformed  polypropylene  or  PVC/PVDC  blisters  with aluminium backing foil.',\n",
       "  '4/56 EMEA 2008 \\x0c Active Substance The is name chemical of  Rivaroxaban 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxzolidin-5-yl}methyl)-2-thiophene-carboxamide.',\n",
       "  'The structure has been  confirmed  with  spectral  data:  IR,  UV-VIS,  1H-NMR,  13C-NMR,  mass  spectrometry  and elementary  analysis.',\n",
       "  'Single-crystal x-ray structural analysis confirms the S configuration of the molecule Rivaroxaban  is  only  slightly  soluble  in  organic  solvents  (e.g.',\n",
       "  'acetone,  polyethylene  glycol 400) and is practically insoluble in water and aqueous media with pH 1 \\xe2\\x80\\x93 9 (pH-independent 5 - 7 mg/L are soluble at 25 \\xc2\\xb0C).',\n",
       "  'Rivaroxaban has been tested for polymorphism and pseudo-polymorphism according to the ICH Q6A guideline  (decision  tree  4).',\n",
       "  '\\xe2\\x80\\xa2 Manufacture Rivaroxaban  is  synthesised  using  a  five-step  synthetic  process  using  4-(4-nitrophenyl)-3-morpholinone as a starting material.',\n",
       "  'Based on batch analysis data adequate specifications have been  set  to  control  the  quality  of  the  starting  materials,  solvents  and  reagents,  and  isolated intermediates.',\n",
       "  'In practice, only 3 impurities (acetoxamide and bis-oxamine-urea and triamide) and enantiomeric purity are monitored in  batch  analysis.',\n",
       "  'No  single  structurally  known  organic  impurity  is  limited  above  the  limit  of max.0.15%, which would require specific toxicological qualification.',\n",
       "  'have  been  sufficiently  validated  to  meet  the general  requirements  of  the  ICH  guideline  Q2R,  Validation  of  Analytical  Procedures:  Test  and Methodology.',\n",
       "  'The acceptance criteria in the active substance specifications have been set in accordance with ICH Q6A and are based on batch analyses of three representative pilot batches manufactured using the process described intended for marketing and 29 preclinical, clinical and stability batches.',\n",
       "  '\\xe2\\x80\\xa2 Stability Stability data have been provided for three batches of the active substance stored at 25 \\xc2\\xb0C / 60 % RH for 18 months and at 40 \\xc2\\xb0C /75 % RH for six months.',\n",
       "  '5/56 EMEA 2008 \\x0cAdditional stability studies have been performed under stress conditions (thermal, hydrolytic and oxidative stress).',\n",
       "  'Medicinal Product  \\xe2\\x80\\xa2  Pharmaceutical Development The development objective was to provide a small size immediate release tablet formulation of rivaroxaban.',\n",
       "  'Therefore  it  could  be  classified  as  a  Class  II substance in the Biopharmaceutics Classification System (low solubility, high permeability).',\n",
       "  'The problem of the low solubility of the active substance is addressed by reducing its particle size with micronisation to increase the particle surface area and thus facilitate dissolution.',\n",
       "  'Dissolution profiles obtained on micronised batches of rivaroxaban were compared to non-micronised (crystalline) ones and  the  results  support  the  need  for  micronisation  of  the  active  substance.',\n",
       "  'When  comparing  the dissolution  kinetics  of  micronised  active  substance  within  the  specified  limits  of  particle  size distribution (e.g.',\n",
       "  'For  the  formulation  development  well-known  standard  excipients  that  are  often  used  in  immediate release tablet formulations were employed.',\n",
       "  'Microcrystalline cellulose and lactose monohydrate act as fillers, croscarmellose sodium as a disintegrant, hypromellose 5 cp as a binder, sodium laurilsulfate as a wetting agent and magnesium stearate as a lubricant.',\n",
       "  'The impact of manufacturing process parameters on target properties of the final dosage form, such  as  tablet  hardness,  disintegration,  dissolution,  content  uniformity  and  stability  has  been investigated  during  development  and  scale-up  and  appropriate  operating  ranges  have  been  set  to ensure  that  the  finished  product  is  of  the  intended  quality.',\n",
       "  'Under these conditions  the  tablets  show  nearly  complete  dissolution  (>  80  %)  within  30  minutes  meeting  the requirements  of  the  Ph.Eur.',\n",
       "  'A  series  of other properties of Rivaroxaban tablets that could potentially alter the dissolution profile and the in-vivo  bioavailability  were  also  investigated  and  the  suitability  of  the  test  method  to  differentiate between  batches  was  evaluated.',\n",
       "  'The  aspects  that  were  challenged  included  the  influence  of disintegrant; granulation time; blending time; addition of wetting agent; accelerated stability testing and compression force.',\n",
       "  'The  relevance  of  the  specifications  set  for  the  active  substance  particle  size  distribution  has  been confirmed by in vivo studies in dogs showing that the oral absorption is independent on API particle size after administration of tablets manufactured with API within the proposed specification limits.',\n",
       "  '\\xe2\\x80\\xa2  Manufacture of the Product The manufacturing process is a standard process for these kinds of formulations and consists of the following main steps: fluidised-bed granulation, mixing, tabletting and film-coating.',\n",
       "  'Although the proposed manufacturing process has not been validated at commercial scale, the batch analysis  data  collected  for  five  pilot  batches  and  three  production  scale  batches,  the  established  in process  controls  and  the  fact  that  the  process  is  standard  and  well-characterised  provide  sufficient grounds  to  conclude that  it  is  sufficiently  robust  and  can  reproducibly  produce  finished  product  of consistent quality complying with the approved specification.',\n",
       "  'In addition the applicant has committed to  perform  the  validation  with  three  consecutive  commercial  scale  batches  in  accordance  with  the approved validation protocol as a post approval commitment.',\n",
       "  'Paddle apparatus), uniformity of dosage units (Ph.Eur), impurities and microbial purity (Ph.',\n",
       "  'The  specification  and  control  tests  applied  for  the  finished  product  at  time  of  release  and throughout the life of the product, are in compliance with general pharmacopoeial standards (including Ph Eur) and ICH guidelines (Q3B and Q6A).',\n",
       "  'The  parameters  tested  were  appearance,  assay,  degradation  products,  dissolution,  hardness, disintegration, water and microbial purity (at selected time points).',\n",
       "  'In conclusion the stability results presented were satisfactory and support the proposed shelf life for the commercially packaged product under the conditions specified in the SPC.'],\n",
       " 'top_n_summary': [' Introduction  in  subjects  undergoing  hip  or  knee  arthroplasty.',\n",
       "  'LDUH,  however, the  only  method  of is is  not  recommended  as Xarelto  contains  rivaroxaban  as  the  active  substance.',\n",
       "  'It  is  presented  as  immediate-release film-coated tablet containing 10 mg of rivaroxaban for oral use.',\n",
       "  'Other ingredients in the core tablet include cellulose microcrystalline, croscarmellose sodium, hypromellose  5  cp,  lactose  monohydrate,  magnesium  stearate  and  sodium  laurilsulfate.',\n",
       "  'The  film coating contains ferric oxide red, hypromellose 15 cp, macrogol 3350 and titanium dioxide  The  tablets  are  packaged  in  thermoformed  polypropylene  or  PVC/PVDC  blisters  with aluminium backing foil.',\n",
       "  '4/56 EMEA 2008 \\x0c Active Substance The is name chemical of  Rivaroxaban 5-Chloro-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-1,3-oxzolidin-5-yl}methyl)-2-thiophene-carboxamide.',\n",
       "  'It is a white to yellowish powder with a molecular weight of 435.89.',\n",
       "  'The empirical formula and the relative molecular mass of rivaroxaban have been confirmed by elementary analysis and mass spectrometry.',\n",
       "  'The structure has been  confirmed  with  spectral  data:  IR,  UV-VIS,  1H-NMR,  13C-NMR,  mass  spectrometry  and elementary  analysis.',\n",
       "  'The 1,3-oxazolidin  ring  system  has  in  position  5  a  chiral carbon-atom  with  (S) configuration.',\n",
       "  'Single-crystal x-ray structural analysis confirms the S configuration of the molecule Rivaroxaban  is  only  slightly  soluble  in  organic  solvents  (e.g.',\n",
       "  'acetone,  polyethylene  glycol 400) and is practically insoluble in water and aqueous media with pH 1 \\xe2\\x80\\x93 9 (pH-independent 5 - 7 mg/L are soluble at 25 \\xc2\\xb0C).',\n",
       "  'The partition coefficient in octanol / water (log Po/w ) is 1.5.',\n",
       "  'Rivaroxaban has been tested for polymorphism and pseudo-polymorphism according to the ICH Q6A guideline  (decision  tree  4).',\n",
       "  'Rivaroxaban  crystallizes  in  three  polymorphs.',\n",
       "  'The identity of polymorph I is routinely controlled by Raman spectroscopy at release.',\n",
       "  '\\xe2\\x80\\xa2 Manufacture Rivaroxaban  is  synthesised  using  a  five-step  synthetic  process  using  4-(4-nitrophenyl)-3-morpholinone as a starting material.',\n",
       "  'Three key intermediates must be synthesised, which are then used in the reaction to form the active substance.',\n",
       "  'After re-crystallization of rivaroxaban crude, the material is micronised.',\n",
       "  'Based on batch analysis data adequate specifications have been  set  to  control  the  quality  of  the  starting  materials,  solvents  and  reagents,  and  isolated intermediates.',\n",
       "  'Eighteen  process  impurities  originating  from  the  starting  materials  and  the  synthetic  process have  been  identified.',\n",
       "  'The  origin  of  each  impurity  has  been  discussed  and  the  structure  of  each impurity has been described based on spectral analysis data (NMR and spectrometry).',\n",
       "  'In practice, only 3 impurities (acetoxamide and bis-oxamine-urea and triamide) and enantiomeric purity are monitored in  batch  analysis.',\n",
       "  'No  single  structurally  known  organic  impurity  is  limited  above  the  limit  of max.0.15%, which would require specific toxicological qualification.',\n",
       "  'The  solvents  used  in  the  synthesis  have  been  shown  to  be  efficiently  removed  during  the purification and drying operations and appropriate specifications have been set.',\n",
       "  '\\xe2\\x80\\xa2  Specification The active substance specification includes tests for appearance, colour of solution, identification (IR, high performance liquid chromatography (HPLC), assay (HPLC), enantiomeric purity, polymorph I (Raman spectra), particle size (laser diffraction), related impurities (HPLC), residual solvents (GC), water content (Karl-Fischer), sulphated ash (Ph.',\n",
       "  'Eur), heavy metals (Ph.',\n",
       "  'Eur) and microbial purity (Ph.',\n",
       "  'The  analytical  methods  not  described in  Ph.Eur.',\n",
       "  'have  been  sufficiently  validated  to  meet  the general  requirements  of  the  ICH  guideline  Q2R,  Validation  of  Analytical  Procedures:  Test  and Methodology.',\n",
       "  'The acceptance criteria in the active substance specifications have been set in accordance with ICH Q6A and are based on batch analyses of three representative pilot batches manufactured using the process described intended for marketing and 29 preclinical, clinical and stability batches.',\n",
       "  'All results comply with the specification and demonstrate consistent quality of the batches produced.',\n",
       "  '\\xe2\\x80\\xa2 Stability Stability data have been provided for three batches of the active substance stored at 25 \\xc2\\xb0C / 60 % RH for 18 months and at 40 \\xc2\\xb0C /75 % RH for six months.',\n",
       "  'In all cases the results met the predefined quality conditions set at the time of the testing.',\n",
       "  'There was no degradation, or increase in the water content and no trends were identified.',\n",
       "  '5/56 EMEA 2008 \\x0cAdditional stability studies have been performed under stress conditions (thermal, hydrolytic and oxidative stress).',\n",
       "  'The photostability of the active substance was tested according to the requirements of ICH Q1B.',\n",
       "  'The results have shown that the active substance, when in solid state, is stable with regards to the influence of light and therefore there is no need to take any packaging and storage precautions against light.',\n",
       "  'Medicinal Product  \\xe2\\x80\\xa2  Pharmaceutical Development The development objective was to provide a small size immediate release tablet formulation of rivaroxaban.',\n",
       "  'The active substance is practically insoluble in water and it has a high permeability as shown  by  the  results  of  a  validated  Caco-2  assay.',\n",
       "  'Therefore  it  could  be  classified  as  a  Class  II substance in the Biopharmaceutics Classification System (low solubility, high permeability).',\n",
       "  'The problem of the low solubility of the active substance is addressed by reducing its particle size with micronisation to increase the particle surface area and thus facilitate dissolution.',\n",
       "  'Dissolution profiles obtained on micronised batches of rivaroxaban were compared to non-micronised (crystalline) ones and  the  results  support  the  need  for  micronisation  of  the  active  substance.',\n",
       "  'When  comparing  the dissolution  kinetics  of  micronised  active  substance  within  the  specified  limits  of  particle  size distribution (e.g.',\n",
       "  'X90 < 15 \\xc2\\xb5m), significant differences of dissolution kinetics can not be observed.',\n",
       "  'For  the  formulation  development  well-known  standard  excipients  that  are  often  used  in  immediate release tablet formulations were employed.',\n",
       "  'Microcrystalline cellulose and lactose monohydrate act as fillers, croscarmellose sodium as a disintegrant, hypromellose 5 cp as a binder, sodium laurilsulfate as a wetting agent and magnesium stearate as a lubricant.',\n",
       "  'Lactose monohydrate is produced from milk from  healthy  animals  in  the  same  conditions  as  milk  collected  for  human  consumption  and  the magnesium stearate used is of vegetable origin only.',\n",
       "  'A comprehensive discussion on process development has been provided by the applicant.',\n",
       "  'A standard fluid  bed  granulation  process  has  been  developed,  followed  by  final  mixing,  tabletting  and  film-coating.',\n",
       "  'The impact of manufacturing process parameters on target properties of the final dosage form, such  as  tablet  hardness,  disintegration,  dissolution,  content  uniformity  and  stability  has  been investigated  during  development  and  scale-up  and  appropriate  operating  ranges  have  been  set  to ensure  that  the  finished  product  is  of  the  intended  quality.',\n",
       "  'The  tablet  composition  and  operating principles of all parts of the manufacturing process were not changed during scale-up.',\n",
       "  'The  tablet  dissolution  rate  is  a  critical  quality  attribute  of  the  product  and  is  influenced  by  active substance particle size.',\n",
       "  'Therefore a discriminating dissolution test method has been developed for the release of the product.',\n",
       "  'The dissolution test is performed in an acetate buffer of pH 4.5.',\n",
       "  'Under these conditions  the  tablets  show  nearly  complete  dissolution  (>  80  %)  within  30  minutes  meeting  the requirements  of  the  Ph.Eur.',\n",
       "  'It  has  been  shown  that  the  developed  dissolution  test  is  able  to discriminate  between  tablets  containing  different  particle  sizes  of  the  active  substance.',\n",
       "  'A  series  of other properties of Rivaroxaban tablets that could potentially alter the dissolution profile and the in-vivo  bioavailability  were  also  investigated  and  the  suitability  of  the  test  method  to  differentiate between  batches  was  evaluated.',\n",
       "  'The  aspects  that  were  challenged  included  the  influence  of disintegrant; granulation time; blending time; addition of wetting agent; accelerated stability testing and compression force.',\n",
       "  'In all cases the discriminatory power of the dissolution test was sufficiently demonstrated.',\n",
       "  'The  relevance  of  the  specifications  set  for  the  active  substance  particle  size  distribution  has  been confirmed by in vivo studies in dogs showing that the oral absorption is independent on API particle size after administration of tablets manufactured with API within the proposed specification limits.',\n",
       "  'Different product formulations have been used in the early studies.',\n",
       "  'However bioequivalence between the clinical trial formulations and the one intended for marketing has been demonstrated.',\n",
       "  'Rivaroxaban  coated  tablet  10  mg  are  packaged  in  PP-  or  PVC-aluminium  blister.',\n",
       "  'The  immediate packaging materials are commonly used for these types of formulations and complies with 6/56 EMEA 2008 \\x0cPh.',\n",
       "  'The  stability  studies  indicate  that  the  primary  packaging  is  suitable  for maintaining drug product quality.',\n",
       "  '\\xe2\\x80\\xa2  Manufacture of the Product The manufacturing process is a standard process for these kinds of formulations and consists of the following main steps: fluidised-bed granulation, mixing, tabletting and film-coating.',\n",
       "  'All critical process parameters have been identified and controlled by appropriate in process controls.',\n",
       "  'Although the proposed manufacturing process has not been validated at commercial scale, the batch analysis  data  collected  for  five  pilot  batches  and  three  production  scale  batches,  the  established  in process  controls  and  the  fact  that  the  process  is  standard  and  well-characterised  provide  sufficient grounds  to  conclude that  it  is  sufficiently  robust  and  can  reproducibly  produce  finished  product  of consistent quality complying with the approved specification.',\n",
       "  'In addition the applicant has committed to  perform  the  validation  with  three  consecutive  commercial  scale  batches  in  accordance  with  the approved validation protocol as a post approval commitment.',\n",
       "  'Paddle apparatus), uniformity of dosage units (Ph.Eur), impurities and microbial purity (Ph.',\n",
       "  'Eur.).',\n",
       "  'The  specification  and  control  tests  applied  for  the  finished  product  at  time  of  release  and throughout the life of the product, are in compliance with general pharmacopoeial standards (including Ph Eur) and ICH guidelines (Q3B and Q6A).',\n",
       "  'The specifications for release and throughout shelf life are identical except uniformity of content and identification.',\n",
       "  'Batch analysis data from 5 pilot scale stability and 3 commercial scale batches have been presented.',\n",
       "  'All batches met the test limits as defined in the release specification and test methodology valid at the time of batch release.',\n",
       "  '\\xe2\\x80\\xa2  Stability of the Product Stability studies were carried out on 3 pilot scale batches of tablets according to the ICH requirements.',\n",
       "  'Samples were stored at 25oC/60 % RH and 30oC/75 % RH for 24 months and in 45oC/75 % RH for 6 months.',\n",
       "  'Additional stability data have been provided from thermal stress test conditions at 60 \\xc2\\xb0C and 80 \\xc2\\xb0C and high humidity stress test conditions (25\\xc2\\xb0C / 60 % RH, 25 \\xc2\\xb0C / 80 % RH, 30 \\xc2\\xb0C / 75 % RH, 40 \\xc2\\xb0C / 75 % RH) in open HDPE bottles for 12 months.',\n",
       "  'Furthermore, bulk stability data at 25 \\xc2\\xb0C / 60 % RH, 30\\xc2\\xb0 C / 75 % RH, and 45 \\xc2\\xb0C / 75 % RH, and photostability data from studies performed in accordance with ICH requirements have been provided.',\n",
       "  'The  parameters  tested  were  appearance,  assay,  degradation  products,  dissolution,  hardness, disintegration, water and microbial purity (at selected time points).',\n",
       "  'The results of the accelerated and long term stability studies show a slight increase in water to an equilibrium state leading to a slight decrease in hardness.',\n",
       "  'However in all cases the hardness results were within the acceptable ranges.',\n",
       "  'No trend and no variability were observed in any of the other tested parameters.',\n",
       "  'The results from the stress studies show that there is no formation or increase of any of the known by-products of the active substance or any unknown compound.',\n",
       "  'In addition the results of the photostability studies demonstrate that both the uncoated and coated tablets are stable upon exposure to light.',\n",
       "  'Therefore there is no need to introduce any storage or transport restrictions in the SPC.',\n",
       "  'In conclusion the stability results presented were satisfactory and support the proposed shelf life for the commercially packaged product under the conditions specified in the SPC.',\n",
       "  'Discussion on chemical, pharmaceutical and biological aspects  The quality of Xarelto is adequately established.',\n",
       "  'In general, satisfactory chemical and pharmaceutical documentation has been submitted for marketing authorization.',\n",
       "  'There are no major deviations from EU and ICH requirements.',\n",
       "  '7/56 EMEA 2008 \\x0cand secondary  pharmacology,  The  active  substance  is  well  characterised  and  documented.',\n",
       "  'It  is  a  class  II  substance  in  the  BCS classification  system.',\n",
       "  'Its  low  aqueous  solubility  is  overcome  by  reducing  the  particle  size  with micronisation.',\n",
       "  'Appropriate limits have been included in the active substance specifications to monitor the particle size and size distribution.',\n",
       "  'Moreover the release of the active from the finished product is controlled routinely with a discriminatory dissolution test.',\n",
       "  'The excipients are commonly used in these types of formulations and comply with Ph.',\n",
       "  'The packaging material is commonly used  and  well  documented.',\n",
       "  'The  manufacturing  process  of  the  finished  product  is  a  standard granulation, tabletting and coating process that has been adequately described.',\n",
       "  'Stability tests indicate that the product under ICH guidelines conditions is chemically stable for the proposed shelf life.']}"
      ]
     },
     "execution_count": 13,
     "metadata": {},
     "output_type": "execute_result"
    }
   ],
   "source": [
    "ll"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 2",
   "language": "python",
   "name": "python2"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 2
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython2",
   "version": "2.7.10"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 2
}
